20 results about "Hepatitis B Virus Antigen" patented technology

The invention belongs to the technical field of immune effect drugs, and discloses a dendritic cell albumin suspension and a preparation method and application thereof.The preparation method of the dendritic cell albumin suspension includes the following steps that isolated mononuclear cells PBMC are collected, and matured DCs are cultured in a laminar flow purification laboratory; loading the multi-valence hepatitis B virus antigen epitope peptide on the DC; and the DC cell albumin suspension is prepared. The CTL immune effect excited by the DC can effectively remove HBV viruses in an integrated state in liver cells, so that the conditions of patients with hepatitis B and cirrhosis are reversed until HBV antigens are negative, and the conditions are relieved fundamentally; in the immune response excited by DC, the effector CTL cells immediately play a role in clearing HBV viruses, and the memory T lymphocytes play a role in clearing HBV viruses in vivo for a long time, so that the condition of hepatitis B is continuously reversed. Reagents used in the DC culture process are completely localized. The cost is greatly reduced and is obviously lower than that of foreign countries, and popularization is facilitated; china gets rid of the history of long-term dependence on imported anti-hepatitis B viruses.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen. The amino acid sequence of the epitope peptide comprises any one or more of SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL LATWVGSNL (Lattice, Attention, an RRMETTVNA (radio frequency identification tag); mAARVCCQL is used as a template; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The invention discloses a lentiviral vector and lentiviral vector particles for treating hepatitis B infection. The lentiviral vector and particles of the invention contain a nucleotide sequence coding an hepatitis B virus antigen. The large S antigen of hepatitis B virus was in particular selected as candidate and can be applied in pharmaceutical compositions or vaccines for treating and / or preventing hepatitis B virus infection or treating and / or preventing diseases caused by hepatitis B virus infection, which has excellent therapeutic and preventive effects in subjects in need thereof.

Provided in the present application are a glycosylated fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use thereof. A first aspect of the present application provides the glycosylated fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment, the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332, the glycosylation modification does not comprise sialic acid modification, and the positions are numbered according to the EU numbering system. The fusion protein can bind to DC cells and activate DC cells, and thus promote the proliferation and activation of specific T cells.

The invention discloses a screening method of hepatitis B virus antigen epitope peptides, computer equipment and a storage medium, and the method comprises the following steps: generating an initial screening library based on all proteome sequences of hepatitis B viruses, the initial screening library comprising a plurality of antigen epitope peptides to be screened; an antigen epitope peptide-MHC compound corresponding to each antigen epitope peptide is constructed; based on the antigen epitope peptide-MHC compound, a conformational trajectory of the antigen epitope peptide-MHC compound is obtained through molecular dynamics simulation; calculating the binding free energy of each antigen epitope peptide and the MHC based on the conformation trajectory, and sorting the plurality of antigen epitope peptides based on the binding free energy to obtain a first sorting set; based on the antigen epitope peptide-MHC compound, sorting the plurality of antigen epitope peptides by using a machine learning model to obtain a second sorting set; and screening the plurality of to-be-screened antigen epitope peptides based on the first sorting set and the second sorting set to obtain the screened antigen epitope peptides.

The application discloses a monoclonal antibody against hepatitis B virus e antigen and a preparation method and application thereof, and relates to the field of hepatitis B antigen detection. Specifically, the antibody provided by the application has HCDR1-3 as shown in SEQ ID NO: 1, 2 and 3 respectively, and LCDR1-3 as shown in SEQ ID NO: 4, 5 and 6 respectively. The provided antibody can specifically recognize human hepatitis B e antigen. The positive coincidence rate, the negative coincidence rate and the total coincidence rate of a detection reagent constructed using the antibody and the Abbott control reagent are all 100%. Compared with an existing antibody 3A3, the stability and the repeatability of detection are significantly improved, and the early detection rate of the reagent kit has important value.

Provided in the present application are a glycosylated fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use thereof. A first aspect of the present application provides the glycosylated fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment, the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332, the glycosylation modification does not comprise sialic acid modification, and the positions are numbered according to the EU numbering system. The fusion protein can bind to DC cells and activate DC cells, and thus promote the proliferation and activation of specific T cells.

The invention discloses an application of host factors DDOST and SEC61A in regulation and control of hepatitis B virus antigen expression and HBV replication. A series of novel host factors for regulating and controlling HBsAg expression are identified, and by screening the host factors, DDOST and SEC61A1 show a strong inhibition effect on hepatitis B virus surface antigens in cell and mouse models, and are expected to be used for developing novel therapeutic drugs and therapeutic strategies for inhibiting the hepatitis B virus surface antigens.

The invention discloses application of a host factor RAB10 in regulation and control of hepatitis B virus antigen expression and anti-hepatitis B virus. The invention provides an application of a host factor RAB10 or a coding gene thereof in regulation and control of hepatitis B virus replication or hepatitis B virus antigen expression level in host cells, and an application of the host factor RAB10 or an expression promoter thereof in preparation of drugs for resisting hepatitis B virus or inhibiting hepatitis B virus antigen. The invention also discloses application of the host factor RAB10 or the coding gene thereof as a drug target in screening drugs for resisting hepatitis B virus or inhibiting hepatitis B virus antigen. Researches show that RAB10 can significantly inhibit HBsAg expression, HBV DNA replication, HBV RNA transcription and HBs protein level, is expected to be used for developing a novel therapeutic drug for inhibiting hepatitis B virus surface antigen, and provides a new strategy for HBV functional cure.

The present invention relates to adenoviral vectors encoding hepatitis B virus antigens fused to herpes virus glycoprotein D and methods of use thereof. Provided herein is the use of a vaccine comprising a nucleic acid molecule encoding nucleotide sequences of a hepatitis B virus (HBV) Core protein, an HBV polymerase N-terminal domain, and an HBV polymerase C-terminal domain in the manufacture of a medicament for inducing an immune response against HBV in a subject. Also provided are non-natural variants of an HBV Core protein, an HBV polymerase N-terminal domain, and an HBV polymerase C-terminal domain, and immunogenic fragments thereof. Also provided are fusion proteins comprising a herpes simplex virus (HSV) variant fused with a glycoprotein (gD) sequence of the HBV variant, and uses of the fusion proteins.

The application provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and application. The first aspect of the application provides a glycosyl-modified fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment; the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330 and glutamic acid at position 332; the glycosylation modification does not comprise sialic acid modification; and the position numbering is according to the EU numbering system. The fusion protein can bind to DC cells, activate DC cells and promote the proliferation and activation of specific T cells.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of LTFGRETVL, LTFGRETVL, LTFGRETVL, LTFGRETVL and LTFGRETVL; aYRPPNAPIL, AYRPPNAPIL ASRELVVSY, ASRELVVSY; an MMWYWGPSL is used as a core; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

Provided herein are vaccine compositions comprising an oligonucleotide and a hepatitis B virus antigen present in the same composition or in a separate composition, which are useful for preventing or treating a hepatitis B virus infection in a subject. These vaccine compositions can exert a sustained immunomodulatory effect and cause a reduction in HBV antigen levels in infected subjects. Also provided herein are methods of making these vaccine compositions and uses thereof.

The invention relates to the field of immunology, and particularly discloses a TCR combination for recognizing hepatitis B virus antigens and application, the TCR combination for recognizing hepatitis B virus antigens comprises a plurality of separated TCRs, the plurality of separated TCR combinations for recognizing hepatitis B virus antigens form four TCR groups, and the four TCR groups comprise a first TCR group, a second TCR group, a third TCR group and a fourth TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the second TCR group specifically recognizes a second antigen epitope, and the amino acid sequence of the second antigen epitope is as shown in SEQ ID NO: 2; the third TCR group specifically recognizes a third antigen epitope, and the amino acid sequence of the third antigen epitope is as shown in SEQ ID NO: 3; the fourth TCR group specifically recognizes a fourth antigen epitope, the amino acid sequence of the fourth antigen epitope is as shown in SEQ ID NO: 4, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention discloses an application of a host factor TMEM40 in regulation and control of hepatitis B virus antigen expression and HBV resistance. According to the invention, a series of novel host factors for regulating and controlling HBsAg expression are identified by utilizing a protein spectrum, and by screening the host factors, the TMEM40 shows a strong inhibition effect on hepatitis B virus surface antigens in a cell model, and the effect of the TMEM40 gene in inhibiting hepatitis B virus is provided for the first time. Researches show that TMEM40 is expected to be used for developing a novel therapeutic drug for inhibiting hepatitis B virus surface antigen, and a new strategy is provided for HBV functional cure.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: EEIRLMVFVL; carrying out FSSAGPCAL (FSSAGPCAL); carrying out KSVQHLESL (KSVQHLESL An RVTGGVFLV is adopted; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The invention discloses an application of liquidambar formosana acid in preparation of anti-hepatitis B virus drugs, the liquidambar formosana acid can inhibit the replication of hepatitis B viruses, inhibit the generation and replication of hepatitis B virus antigens, and inhibit the expression of hepatitis B virus mRNA and HBV transcription factors, has a significant inhibitory effect on hepatitis B viruses, and can be used for preparing anti-hepatitis B virus drugs. A new scheme is provided for development of new anti-hepatitis B virus drugs, and the liquidambar formosana acid serving as a traditional Chinese medicinal material is rich in medicinal resource and low in cost and has important significance in research and development of the novel anti-hepatitis B virus drugs.

The present invention discloses the use of passutonic acid in the preparation of anti-hepatitis B virus drugs. Passutonic acid can inhibit the replication of hepatitis B virus, inhibit the production and replication of hepatitis B virus antigens, and inhibit the expression of hepatitis B virus mRNA and HBV transcription factors, and has a significant inhibitory effect on hepatitis B virus. It provides a new solution for the development of new anti-hepatitis B virus drugs. Moreover, as a traditional Chinese medicinal material, passutonic acid has abundant medicinal resources and low cost, and is of great significance to the research and development of new anti-hepatitis B virus drugs.

The invention discloses a PEGylated galactosyl modified chitosan oligosaccharide stearylamine disulfide bond graft and a hepatocyte targeting nanoformulation and method thereof, and belongs to the field of synthesis of polymer drug carriers. The PEGylated galactosyl modified chitosan oligosaccharide stearylamine disulfide bond graft provided by the invention comprises chitosan oligosaccharide with a molecular weight of 18.9 kDa, a chitosan oligosaccharide deacetylation degree of 95%, a fatty acid carbon chain length of C18, and an amino substitution degree of 1% to 30%. The PEGylated galactosyl modified chitosan oligosaccharide fatty acid graft has a highly efficient hepatocyte targeting capability, and the PEGylated galactosyl modified chitosan oligosaccharide stearylamine disulfide bond graft drug delivery system can significantly block the expression of hepatitis B virus antigen.